KALV NASDAQ
KalVista Pharmaceuticals, Inc.
1W: +0.2%
1M: +0.8%
3M: +59.4%
YTD: +74.6%
1Y: +100.6%
3Y: +173.3%
5Y: -3.9%
$27.00
Last traded 2026-06-12 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$1.4B
52W Range9.83-27
Volume4,262,878
Avg Volume3,537,050
Beta-0.29
Dividend—
Analyst Ratings
Company Info
CEOBenjamin L. Palleiko
Employees275
SectorHealthcare
IndustryBiotechnology
IPO Date2015-04-09
Websitekalvista.com
200 Crossing Boulevard
Framingham, MA 01702
US
Framingham, MA 01702
US
857 999 0075
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.
Latest News
KalVista Pharmaceuticals (KALV) Upgraded to Buy: What Does It Mean for the Stock?
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Taylor Morrison Home Corporation (NYSE - TMHC), Rallybio Corporation (Nasdaq – RLYB), InMed Pharmaceuticals, Inc. (Nasdaq – INM), KalVista Pharmaceuticals, Inc. (Nasdaq – KALV)
KalVista's (KALV) Chief Development Officer Sells 33,800 Shares for $905,000
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—BNCC, KALV, KW, and LEG
Most and least shorted small-to-mid-cap stocks
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Palleiko Benjamin L | D-Return | 479,989 | — | 2026-06-11 |
| Palleiko Benjamin L | D-Return | 47,354 | $8.39 | 2026-06-11 |
| Palleiko Benjamin L | D-Return | 29,611 | $6.74 | 2026-06-11 |
| Palleiko Benjamin L | D-Return | 33,800 | $7.07 | 2026-06-11 |
| Palleiko Benjamin L | D-Return | 71,700 | $8.21 | 2026-06-11 |